Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Restructurings -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (59)	12/16/2002 5:24:52 PM
From: Icebrg	Read Replies (1) \| Respond to of 270

Even Millennium! 4% Millennium Pharmaceuticals to Cut 103 Jobs in Shift to Product Development CAMBRIDGE, Mass. (AP) -- Biotech company Millennium Pharmaceuticals Inc. said Monday it would lay off 103 workers, including 54 full-timers, as it adjusts its focus from research to product development. The layoffs will be at Millennium's Cambridge, Mass. headquarters. The company also has facilities in South San Francisco, Calif., and Cambridge, England. "Millennium is evolving from an organization that was primarily research-oriented into a product-driven company," the company said in a statement. "It's been part of our long-term business strategy over a very long time and clearly this requires a different range of skills and capabilities, and we are making the organizational changes that reflect this evolution." Millennium has about 2,450 workers worldwide. The layoffs include 49 contract workers. Earlier this month, Millennium announced its cancer-fighting drug Velcade appears to stop or reverse the progression of a deadly form of the disease in six out of 10 patients. The company plans to file for regulatory approval early next year before Phase III trials are complete, but some analysts doubted it would warrant approval under a speeded-up regulatory process. Millennium shares were up 35 cents to close at $9.26 Monday on the Nasdaq Stock Market. They are down from a high of more than $25 earlier this year.

To: Icebrg who wrote (59)	1/13/2003 10:59:48 AM
From: Icebrg	Read Replies (1) \| Respond to of 270

Ontogen, 90 %. By Mike Freeman UNION-TRIBUNE STAFF WRITER January 9, 2003 Ontogen Corp., a Carlsbad drug development company that has raised $100 million over the past decade, has laid off all but a skeleton crew after it failed to raise additional funds. Barry Toyonaga, Ontogen's president and chief executive, said the 100-employee company terminated more than 90 percent of its work force last month – many of them well-paid chemists and scientists. The company now has between five and 10 employees working in more than 70,000 square feet of lab and warehouse space. "The company is not gone, it's just a lot smaller than it used to be," Toyonaga said. "Raising money in this environment has become increasingly challenging." Founded in 1992, privately held Ontogen is among the old guard of Carlsbad's life science companies. It develops small-molecule therapeutic agents to fight cancer, infectious diseases and other chronic medical conditions. Investors included Johnson & Johnson Development Corp., and Allen & Co. In October 2000, Ontogen announced that it had raised $16.4 million through a private offering of its preferred stock. In January 2002, it won a $1.3 million Small Business Innovation Research grant for development of enzyme inhibitors to aid in monitoring blood glucose levels in people with diabetes. But those funds weren't enough to keep Ontogen going at the 100-employee level, Toyonaga said. By the middle of last year, Ontogen hired investment bankers CBIC World Markets to help it find a buyer. Toyonaga, a former Johnson & Johnson scientist, kept his company's workers on board at that time because he believed they would be among Ontogen's most valuable assets. Ontogen also believes the company's burn rate – the speed at which it spends cash – compares favorably with other drug developers, although a company spokeswoman declined to reveal the amount the company spent each month. "A couple of years ago, we were admired for running an organization of that size so inexpensively," Toyonaga said. "Today, people don't care how inexpensively you run it. Anything is too much money." Venture capitalists, stung by losses as the economy soured, have been shying away from putting their money into biotech companies. There are few signs that the investment spigot for biotech will open anytime soon. "I'm certainly not hearing a whole lot of positive comments from CEOs about the ability to raise cash," said Joseph Panetta, president of Biocom, which represents more than 200 biotechs in San Diego. Toyonaga said outside investors own only 30 percent of Ontogen. The company funded operations through research agreements with pharmaceutical companies, including a $40 million deal in 1996 with Germany's Boehringer Ingelheim. Ontogen also had agreements with Novo Nordisk of Denmark and Organon of the Netherlands. Ontogen has completed Phase I clinical trials for one drug, ONT-093. The drug hinders cancer patients from developing resistance to Taxol and other cancer medicines. Ontogen also has another drug, an anti-inflammatory that assists in wound healing, under development. signonsandiego.com